Brief: Decibel Therapeutics Receives European Orphan Drug Designation For Lead Gene Therapy Candidate
30/03/2023 12:50
March 30 (Reuters) - Decibel Therapeutics Inc DBTX.O :
* DECIBEL THERAPEUTICS RECEIVES EUROPEAN ORPHAN DRUG
DESIGNATION
FOR LEAD GENE THERAPY CANDIDATE DB-OTO
* DECIBEL THERAPEUTICS:TO INITIATE PHASE 1/2 CLINICAL TRIAL
OF
DB-OTO IN PATIENTS WITH CONGENITAL HEARING LOSS DUE TO MUTATIONS
OF OTOFERLIN GENE IN H1
Source text for Eikon: ID:nGNX84ZRMM
Further company coverage: DBTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Decibel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Domo, BlackBerry, Rite Aid
U.S. STOCKS ON THE MOVE-Decibel Therapeutics, Affirm Holdings, Medtronic
Decibel rises on FDA's 'fast-track' tag for hearing-loss therapy
Brief: Decibel Therapeutics Says US Food And Drug Administration Had Granted Fast Track Designation For DB-OTO
Decibel Therapeutics Inc reports results for the quarter ended in June - Earnings Summary